Product Images Aripiprazole

This is a tabular representation of the effects of various drugs on the pharmacokinetics of aripiprazole. The drugs are categorized based on their effect as CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, or others. The table shows the fold change and 90% CI of aripiprazole's PK parameters such as AUC and Cmax in the presence of these drugs compared to the reference values without any drug interactions.*

This is a description of the effects of other drugs on the pharmacokinetics of aripiprazole. The data is presented in Figure 2 and includes the fold change and 90% confidence interval of the dehydro-aripiprazole PK. The drugs included in the study are CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs such as valproate and lorazepam. The relative change in Cmaxf is shown on the x-axis.*

This text describes Figure 3 which represents the effects of aripiprazole on the pharmacokinetics of various other drugs. The table shows the fold change and 90% Confidence Interval (CI) for drugs such as extropmethorphan, Swartarin, Revartarin, omeprazole, lamotrigine, valproate, lorazepam, yontane, and O-desmethyivenlafaxine. It also displays the effect of aripiprazole on their AUC, Cmax, DM%PE, and UGTIAL values.*

This appears to be a figure or a chart displaying the effects of intrinsic factors on dehydro-aripiprazole pharmacokinetics. The factors include gender, age, hepatic impairment, and renal impairment. There are numerical values displayed on the axes and different lines showing changes relative to reference. The specifics of the changes and their implications are not clear without more context.*

This is a Kaplan-Meier estimation figure displaying the cumulative proportion of patients with relapse in schizophrenia study 5. The graph shows the proportion of relapse in patients treated with Aripiprazole and a placebo. The proportion increases over time and the number of subjects at risk decreases. The X-axis displays the number of days from randomization, and the Y-axis displays the cumulative proportion with relapse.*